-
公开(公告)号：KR1020080002313A
公开(公告)日：2008-01-04
申请号：KR1020060061063
申请日：2006-06-30
Applicant: 한올바이오파마주식회사
CPC classification number: A61K9/0002 , A61K31/135 , A61K47/61 , A61K47/62
Abstract: Oral pharmaceutical compositions comprising sibutramine are provided to improve biocompatibility of sibutramine having no addition salts by improving solubility and dissolution rate of sibutramine having no addition salts which is poorly water-soluble and simply synthesized, so that they are useful for prevention and treatment obesity. An oral pharmaceutical composition for prevention and treatment obesity comprises 1 part by weight of sibutramine, 0.1-20 parts by weight of inorganic acid, 0.1-20 parts by weight of high molecular compound polymer of 1-40cp and 0.1-20 parts by weight of dispersing agent, wherein the inorganic acid is sulfuric acid, hydrochloric acid, nitric acid, phosphoric acid or carbonic acid; the high molecular compound polymer is saccharide, cellulose derivative, gum, protein, polyvinyl derivative, polymethacrylate copolymer or polyethylene derivative; and the dispersing agent is sodium starch glycolate, calcium carboxymethylcellulose, low substituted hydroxypropylcellulose, croscarmellose sodium, crospovidone, microcrystalline cellulose, hard anhydrous silicic acid, lactose or starch.
Abstract translation: 提供包含西布曲明的口服药物组合物，以通过改善不具有难溶于水并且简单合成的加成盐的西布曲明的溶解度和溶解速率，从而改善其不具有加成盐的西布曲明的生物相容性，从而可用于预防和治疗肥胖症。 用于预防和治疗肥胖症的口服药物组合物包含1重量份的西布曲明，0.1-20重量份的无机酸，0.1-20重量份的1-40cp的高分子化合物聚合物和0.1-20重量份的 分散剂，其中无机酸是硫酸，盐酸，硝酸，磷酸或碳酸; 高分子化合物聚合物是糖，纤维素衍生物，树胶，蛋白质，聚乙烯衍生物，聚甲基丙烯酸酯共聚物或聚乙烯衍生物; 分散剂为羟乙酸淀粉钠，羧甲基纤维素钙，低取代羟丙基纤维素，交联羧甲基纤维素钠，交聚维酮，微晶纤维素，硬质无水硅酸，乳糖或淀粉。
-
公开(公告)号：KR1020070113382A
公开(公告)日：2007-11-29
申请号：KR1020060046145
申请日：2006-05-23
Applicant: 한올바이오파마주식회사
IPC: A61K9/22
CPC classification number: A61K31/155 , A61K9/2027 , A61K9/2054
Abstract: A metformin-extended release tablet formulation is provided to maintain a constant concentration in blood for 24 hours by one time administration per day by gradually releasing a medicinal ingredient at regular speed even with the use of a smaller amount of a matrix agent than a conventional extended release tablet, increase the compatibility of a patient by decreasing the rejection symptoms of taking medicine and be industrially advantageous due to a simple preparation method. A formulation of metformin-extended release tablet comprises 25-75 wt.% of metformin as an active ingredient, a pharmaceutically acceptable hydrophilic polymer mixture and a matrix agent as a hydrophobic material, wherein the hydrophilic polymer is at least two selected from the group consisting of saccharide, gum, protein, polyvinyl derivative and acrylate derivative and the hydrophobic material is at least one selected from the group consisting of a hydrophobic polymer material such as polyvinyl acetate, and poly(ethylacrylate, methylmethacrylate)copolymer, a hydrophobic low molecular material such as a fatty acid and a fatty acid ester, a fatty acid alcohol, wax, and an inorganic material. In the formulation, the hydrophilic polymer and the hydrophobic material are mixed in a weight ratio of 1:1-20:1.
Abstract translation: 提供二甲双胍延长释放片剂制剂以通过每天一次施用维持血液中恒定浓度24小时，即使使用较少量的基质剂比常规延长剂逐渐释放药物成分 释放片剂，通过减少服用药物的排斥症状而增加患者的相容性，并且由于简单的制备方法在工业上是有利的。 二甲双胍延长释放片剂的制剂包含25-75重量％的二甲双胍作为活性成分，药学上可接受的亲水性聚合物混合物和作为疏水材料的基质剂，其中所述亲水性聚合物是选自以下的至少两种： 的糖，树胶，蛋白质，聚乙烯衍生物和丙烯酸酯衍生物，疏水性材料是选自疏水性聚合物材料如聚乙酸乙烯酯和聚（丙烯酸乙酯，甲基丙烯酸甲酯）共聚物中的至少一种，疏水性低分子材料 作为脂肪酸和脂肪酸酯，脂肪酸醇，蜡和无机材料。 在制剂中，亲水性聚合物和疏水性材料以1：1-20：1的重量比混合。
-
公开(公告)号：KR100780553B1
公开(公告)日：2007-11-29
申请号：KR1020050075923
申请日：2005-08-18
Applicant: 한올바이오파마주식회사
IPC: A61K9/22 , A61K31/155
CPC classification number: A61K9/0065 , A61K9/2054 , A61K9/2866 , A61K31/155
Abstract: 본 발명은 메트포르민 서방정 및 그의 제조방법에 관한 것으로서, 보다 상세하게는 인슐린 비의존형 당뇨병 치료제의 유효성분인 메트포르민과 상기한 메트포르민의 방출속도를 조절할 수 있는 서방성 고분자 중합체를 포함하는 조성물을 소정 조건의 압력으로 슬러그화한 후 건식 과립법에 따라 타정하여 정제층을 형성시키고, 그 표면에 필름상의 코팅층을 형성시킴으로써, 기존의 제품과 비교하여 체내에서 일정한 속도로 24시간 동안 서서히 방출시킬 수 있는 우수한 용출 특성을 나타내어 1일 1회 투여로 24시간 동안 일정한 혈중 농도를 유지하며, 또한 생물학적 동등성을 나타내는 개선된 메트포르민 서방정 및 그의 제조방법에 관한 것이다.
메트포르민, 당뇨병, 서방정Abstract translation: 本发明的它是二甲双胍缓释片剂，并涉及其制造方法，组合物更特别地包括持续释放聚合物，可以调整与的抗糖尿病药NIDDM二甲双胍的预定条件中的活性成分，所述二甲双胍的释放速率 在压力形成片剂层炉渣屏幕之后根据干式造粒法任命的其他，通过形成在其表面上的膜的覆盖层，与常规的产品优越的洗脱可以慢慢释放24小时，在体内的恒定速率相比 本发明涉及以每天一次给药维持24小时恒定血液浓度并显示生物学等效性的改善的二甲双胍缓释制剂及其制备方法。
-
公开(公告)号：KR1020160141045A
公开(公告)日：2016-12-08
申请号：KR1020150073886
申请日：2015-05-27
Applicant: 한올바이오파마주식회사
Abstract: 본발명은보센탄을포함하는약학적조성물에관한것으로, 보다상세하게는난용성약물인보센탄을가용화하여투여용량을감소할수 있고, 혈중농도편차를감소시키는보센탄을함유한약학적조성물에관한것이다. 본발명에의해보센탄, 그약학적으로허용가능한염 또는그 용매화물의투여량을감소할수 있어, 의약품제조에소요되는비용및 환자의부담비용을줄일수 있다. 더불어, 흡수량의편차를개선함으로써치료효과상승은물론부작용발생을감소시킬수 있는효과가있다. 또한, 본발명에의해보센탄을포함하는경구제제를효과적으로제조할수 있다.
-
25.发明公开
公开(公告)号：KR1020130074808A
公开(公告)日：2013-07-05
申请号：KR1020110136687
申请日：2011-12-16
Applicant: 한올바이오파마주식회사
IPC: A61K31/41 , A61K31/4164 , A61P21/00
CPC classification number: A61K31/4178 , A61K31/00 , A61K31/351 , A61K31/402
Abstract: PURPOSE: A pharmaceutical composition containing losartan or a pharmaceutically acceptable salt thereof is provided to ensure a pharmacological effect for preventing or treating hypertension, and to prevent or treat muscle-related side effects caused by administration of statin-based drug. CONSTITUTION: A pharmaceutical composition for preventing or treating muscle toxicity due to a statin-based lipid lowering agent contains losartan or a pharmaceutically acceptable salt thereof as an active ingredient. Losartan or the pharmaceutically acceptable salt is simultaneously and sequentially administered with the statin-based lipid lowering agent. The pharmaceutical composition is also used for preventing or treating hypertension. The muscle toxicity is one or more side effects selected from the group consisting of myositis, myopathy, rhabdomyolysis, and myalgia. [Reference numerals] (AA) CK concentration change rate (%); (BB) Administration time (week); (CC) 40mg/kg of atorvastatin administration group; (DD) 40mg/kg of atorvastatin + 100mg/kg of losartan simultaneous administration group; (EE) 80mg/kg of atorvastatin administration group; (FF) 80mg/kg of atorvastatin + 200mg/kg of losartan simultaneous administration group; (GG) 80mg/kg of atorvastatin + 200mg/kg of losartan time interval administration group
Abstract translation: 目的：提供含有氯沙坦或其药学上可接受的盐的药物组合物，以确保预防或治疗高血压的药理作用，以及预防或治疗由给予他汀类药物引起的肌肉相关副作用。 构成：用于预防或治疗由于基于他汀类的降脂剂引起的肌肉毒性的药物组合物含有氯沙坦或其药学上可接受的盐作为活性成分。 氯沙坦或其药学上可接受的盐同时并依次给予他汀类降脂药。 药物组合物也用于预防或治疗高血压。 肌肉毒性是选自肌炎，肌病，横纹肌溶解症和肌痛的一种或多种副作用。 （附图标记）（AA）CK浓度变化率（％） （BB）行政时间（周）; （CC）40mg / kg阿托伐他汀给药组; （DD）40mg / kg阿托伐他汀+ 100mg / kg氯沙坦同时给药组; （EE）80mg / kg阿托伐他汀给药组; （FF）80mg / kg阿托伐他汀+ 200mg / kg氯沙坦同时给药组; （GG）80mg / kg阿托伐他汀+ 200mg / kg氯沙坦时间间隔给药组
-
Patent Agency Ranking26.发明授权
公开(公告)号：KR101104912B1
公开(公告)日：2012-01-12
申请号：KR1020090001170
申请日：2009-01-07
Applicant: 한올바이오파마주식회사
IPC: C07D213/80 , A61K31/4406 , A61P3/10 , A61P3/06
CPC classification number: C07D213/80
Abstract: 본 발명은 N,N-디메틸 이미도디카르본이미딕 디아미드의 니코틴산염, 그의 제조방법 및 그를 포함하는 약제학적 조성물에 관한 것으로서, 더욱 상세하게는 용해도, 안정성, 비흡습성, 정제 제형으로서의 가공성 등의 물리화학적 성질이 개선되었을 뿐 아니라, 독성이 낮고, N,N-디메틸 이미도디카르본이미딕 디아미드가 본질적으로 발휘하는 약화학적 특성인 당뇨 및 당뇨병, 비만증, 고지혈증, 지방간, 관상동맥질환, 골다공증, 다낭성 난소증후군 등이 복합적으로 나타나는 이른바 대사성 증후군을 지닌 자들의 당뇨병 치료, 당뇨병자의 합병증의 근본 핵심 원인 물질인 중성 지질 저하 작용에 의한 합병증 예방 및 치료 그리고 p53 유전자가 결여된 암, 근육통, 근육세포 독성 및 횡문근 융해의 예방 및 치료 효과를 더욱 증가시켜줄 수 있는 치료제로서 유� ��한 N,N-디메틸 이미도디카르본이미딕 디아미드의 니코틴산염, 그의 제조방법과 그의 약제학적 조성물에 관한 것이다.
메트포르민, 메트포르민 니코틴산염, 메트포르민 이니코틴산염, N,N-디메틸 이미도디카르본이미딕 디아미드, 니코틴산염, 결정성 산부가염, 당뇨병, 대사성증후군-
公开(公告)号：KR1020110129405A
公开(公告)日：2011-12-01
申请号：KR1020117021779
申请日：2010-02-26
Applicant: 한올바이오파마주식회사
IPC: A61K9/22 , A61K31/165 , A61K31/44 , A61K47/48
CPC classification number: A61K31/165 , A61K9/209 , A61K31/44 , A61K9/20 , A61K47/50
Abstract: PURPOSE: A pharmaceutical formulation comprising an immediate release fraction and a sustained release fraction is provided to induce optimal pharmacological effects. CONSTITUTION: A pharmaceutical formulation comprises an immediate release fraction containing rennin inhibitors as a pharmacologically active ingredient; and a sustained release fraction containing dihydropyridine calcium channel blockers as a pharmacologically active ingredient. The rennin inhibitor is aliskiren hemi-fumarate. The calcium channel blocker is amlophidine besylate salt. The pharmaceutical formulation is used for preventing or treating metabolic syndrome, cardiovascular diseases, and renal disorders.
Abstract translation: 目的：提供包含立即释放级分和持续释放级分的药物制剂以诱导最佳药理作用。 构成：药物制剂包含含有凝乳酶抑制剂作为药理活性成分的速释级分; 以及含有二氢吡啶类钙通道阻断剂作为药理活性成分的缓释级分。 肾素抑制剂是阿利吉仑半富马酸盐。 钙通道阻断剂是苯磺酸苯磺酸盐。 药物制剂用于预防或治疗代谢综合征，心血管疾病和肾脏疾病。
-
28.发明公开
公开(公告)号：KR1020110117758A
公开(公告)日：2011-10-28
申请号：KR1020100037154
申请日：2010-04-22
Applicant: 한올바이오파마주식회사
Abstract: 본 발명은 약리학적 활성성분으로 베타 아드레날린 차단제를 포함하는 선방출성 구획, 및 약리학적 활성성분으로 HMG-CoA 환원효소 억제제를 포함하는 지연방출성 구획을 포함하는 약제학적 제제를 제공한다. 본 발명의 약제학적 제제는 고지혈증, 관상 동맥 질환 등이 복합적으로 나타나는 고혈압 환자들의 치료와 합병증 예방에 유용하고, 약물간 상호작용에 따른 부작용 감소에 효과적이다.
-
29.发明公开Ｎ,Ｎ―디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제 无效N，N-二甲基咪唑偶氮二异丁酸丁酯，其制备方法，包含其的药物组合物和包括其的组合制剂
公开(公告)号：KR1020110007985A
公开(公告)日：2011-01-25
申请号：KR1020100069244
申请日：2010-07-16
Applicant: 한올바이오파마주식회사
IPC: C07C279/26 , C07C277/00 , A61K31/155 , A61P3/10
CPC classification number: A61K31/155 , C07C53/124 , C07C279/26
Abstract: PURPOSE: N,N-dimethyl imidodicarbonimidic diamide butyrate is provided to ensure excellent physicochemical properties such as solubility, stability, hygroscopicity and adsorption preventing property, processibility of formulations. CONSTITUTION: A metformin butyrate is represented by chemical formula 1. The metformin butyrate has a crystal form. A melting point of the crystal form is 162°C. A method for preparing the metformin butyrate represented by chemical formula 1 comprises the steps of: reacting metformin hydrochloride represented by chemical formula 2 with base in an organic solvent to prepare metformin free base represented by chemical formula 3; and reacting the metformin free base with butyric acids.
Abstract translation: 目的：提供N，N-二甲基亚氨基二酰亚胺二酰胺丁酸酯，以确保优异的物理化学性质，如溶解度，稳定性，吸湿性和吸附防止性能，配方的加工性。 构成：二甲双胍丁酸酯由化学式1表示。二甲双胍丁酸酯具有晶体形式。 晶体的熔点为162℃。 由化学式1表示的制备丁酸二甲双胍的方法包括以下步骤：将由化学式2表示的二甲双胍盐酸盐与碱在有机溶剂中反应制备由化学式3表示的游离二甲双胍碱; 并使二甲双胍游离碱与丁酸反应。
-
公开(公告)号：KR1020100112292A
公开(公告)日：2010-10-19
申请号：KR1020090030730
申请日：2009-04-09
Applicant: 한올바이오파마주식회사
IPC: A61K47/34 , A61K31/405 , A61P3/06 , A61P9/10
CPC classification number: A61K31/405 , A61K9/1641 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/209 , A61K9/4808 , A61K9/4866 , A61K9/5084
Abstract: PURPOSE: A pharmaceutatin composition of fluvastatin is provided to prevent and treat hyperlipidemia or hepatitis C virus. CONSTITUTION: A pharmaceutical composition for reducing cholesterol contains fluvastatin, pharmaceutically acceptable salt or isomer thereof and poloxamer. The pharmaceutically acceptable salt of fluvastatin is fluvastatin sodium salt. The poloxamer is poloxamer 407 or 188. The poloxamer is contained in 1-500 weight parts based on 100 weight parts of fluvastatin. The composition additionally contains Ursodeoxycholic acid or hydrochlorothiazit as an active ingredient. A pharmaceutical composition for preventing or treating hyperlipidemia, cardiovascular diseases or artery scleroma contains fluvastatin, pharmaceutically acceptable salt or isomer thereof and poloxamer.
Abstract translation: 目的：提供氟伐他汀的药物组合物，用于预防和治疗高脂血症或丙型肝炎病毒。 构成：用于降低胆固醇的药物组合物含有氟伐他汀，其药学上可接受的盐或异构体和泊洛沙姆。 氟伐他汀的药学上可接受的盐是氟伐他汀钠盐。 泊洛沙姆是泊洛沙姆407或188。基于100重量份氟伐他汀，泊洛沙姆包含1-500重量份。 组合物另外含有熊去氧胆酸或氢氯噻嗪作为活性成分。 用于预防或治疗高脂血症，心血管疾病或动脉硬化的药物组合物含有氟伐他汀，其药学上可接受的盐或异构体和泊洛沙姆。
-
-
-
-
-
-
-
-
-
Search Results
108
records
(took 0.029 seconds)
